Ujvira 160 mg Injection Ujvira 160 mg Injection contains trastuzumab emtansine (T-DM1), a targeted anticancer medicine used for the treatment of HER2-positive breast cancer. It combines trastuzumab, which targets HER2-positive cancer cells, with emtansine, a chemotherapy component. Ujvira is administered as an intravenous infusion under the supervision of a qualified healthcare professional.

Effects & Benefits Targets HER2-positive cancer cells. Helps slow or stop the growth of HER2-positive breast cancer cells. Used in eligible patients with HER2-positive breast cancer. Delivers the chemotherapy component directly to HER2-expressing cancer cells. May be used in appropriate patients with early or advanced HER2-positive breast cancer according to the oncologist's treatment plan.